Blinatumomab for B-cell Acute Lymphoblastic Leukemia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
B-cell Acute Lymphoblastic Leukemia+2 MoreBlinatumomab - Drug
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new treatment for leukemia, which uses cells from another person, followed by a different drug, can help reduce relapse rates and improve survival.

Eligible Conditions
  • B-cell Acute Lymphoblastic Leukemia
  • B-Cell Acute Lymphoblastic Leukemia (ALL), Childhood
  • Childhood Acute Lymphoblastic Leukemia (ALL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Blinatumomab
1
Blinatumomab
1
Blinatumomab

Study Objectives

1 Primary · 12 Secondary · Reporting Duration: Days +19, +91, +135 and +180 post-HCT

Year 1
Patient Reported Outcomes
Year 1
Engraftment
Day +100 post-HCT
Percentage of patients who are able to receive the blinatumomab infusion [Feasibility]
Year 1
Acute & Chronic GVHD
Year 1
Primary Graft Failure
Year 1
Secondary Graft Failure
Year 1
Disease Free Survival
Overall Survival
Year 1
Treatment Related Mortality
Day of HCT to Day +180 post-HCT
Cumulative incidence of treatment-related adverse events [Tolerability]
Year 1
Relapse
Days +19, +91, +135 and +180 post-HCT
Analysis of immune cell phenotyping
Functional assessment of lymphocyte subsets
Serum cytokine analysis
Year 1
Persistence of Minimal Residual Disease (MRD) Negativity
Day 0
Length of Stay

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Blinatumomab
1
Blinatumomab
1
Blinatumomab

Side Effects for

Blinatumomab
80%Pyrexia
41%Nausea
35%Headache
30%Vomiting
22%Anaemia
20%Diarrhoea
17%Stomatitis
17%Mucosal inflammation
13%Hypertension
13%Rash
13%Abdominal pain
13%Platelet count decreased
11%Hypokalaemia
11%Erythema
11%Pruritus
11%Hypogammaglobulinaemia
11%Hypotension
9%Neutropenia
9%Epistaxis
9%Tremor
9%Constipation
9%Neutrophil count decreased
7%Agitation
7%Cough
7%Thrombocytopenia
7%Abdominal pain upper
7%Fluid overload
7%Immunodeficiency
7%White blood cell count decreased
7%Alanine aminotransferase increased
6%Fatigue
6%Nasopharyngitis
6%Paronychia
6%Back pain
6%Rash maculo-papular
6%Febrile neutropenia
6%Petechiae
6%Urticaria
6%Decreased appetite
4%Seizure
4%Oropharyngeal pain
4%Aplasia
4%Pain in extremity
4%Neurological symptom
4%Fluid balance positive
4%Aspartate aminotransferase increased
2%Oral pain
2%Hypertransaminasaemia
2%Klebsiella infection
2%Perineal cellulitis
2%Catheter placement
2%Antithrombin III decreased
2%Haematoma
2%Accidental overdose
2%Rhinitis
2%Neurological examination abnormal
2%Body temperature increased
2%Nervous system disorder
2%Blood immunoglobulin G decreased
2%Herpes virus infection
This histogram enumerates side effects from a completed 2022 Phase 3 trial (NCT02393859) in the Blinatumomab ARM group. Side effects include: Pyrexia with 80%, Nausea with 41%, Headache with 35%, Vomiting with 30%, Anaemia with 22%.

Trial Design

2 Treatment Groups

Alpha/beta T-cell and B-cell Depleted, Myeloablative HCT
1 of 2
Alpha/beta T-cell and B-cell Depleted, Reduced Intensity HCT
1 of 2

Experimental Treatment

25 Total Participants · 2 Treatment Groups

Primary Treatment: Blinatumomab · No Placebo Group · Phase 2

Alpha/beta T-cell and B-cell Depleted, Myeloablative HCTExperimental Group · 2 Interventions: Blinatumomab, Alpha/Beta T-cell and B-cell depleted HCT · Intervention Types: Drug, Device
Alpha/beta T-cell and B-cell Depleted, Reduced Intensity HCTExperimental Group · 2 Interventions: Blinatumomab, Alpha/Beta T-cell and B-cell depleted HCT · Intervention Types: Drug, Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blinatumomab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: days +19, +91, +135 and +180 post-hct

Who is running the clinical trial?

AmgenIndustry Sponsor
1,296 Previous Clinical Trials
1,328,559 Total Patients Enrolled
2 Trials studying B-cell Acute Lymphoblastic Leukemia
35 Patients Enrolled for B-cell Acute Lymphoblastic Leukemia
University of Wisconsin, MadisonOTHER
1,070 Previous Clinical Trials
2,576,616 Total Patients Enrolled
1 Trials studying B-cell Acute Lymphoblastic Leukemia
36 Patients Enrolled for B-cell Acute Lymphoblastic Leukemia
Medical College of WisconsinLead Sponsor
566 Previous Clinical Trials
1,154,143 Total Patients Enrolled
Rachel Phelan, MD, MPHStudy ChairMedical College of Wisconsin

Eligibility Criteria

Age < 65 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have had a first remission with persistent disease identified as end of consolidation (EOC) MRD > 0.01%.
You must be younger than 25 years of age.\n
You have had a relapse or greater.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top